Accra has turned down a proposed health agreement with Washington, citing demands for access to medical records and pathogen information, alongside alleged restrictions on the country’s control over medicines. The decision has reignited a continent-wide conversation about health sovereignty.
Accra — Ghana has raised a question that stretches far beyond the boundaries of its own health system: what is a nation’s sovereignty worth when foreign financial aid comes with sensitive conditions attached?
Accra’s answer is now clear: not $109 million.
The Ghanaian government has declined a new health agreement proposed by the United States, which would have delivered roughly $109 million in American funding over five years. The broader package was valued at approximately $300 million, factoring in expected complementary contributions from Ghana.
President John Dramani Mahama confirmed and explained the rejection during remarks at the Council on Foreign Relations in New York on September 25.
And his words struck a chord.
“Who takes another country’s medical records?”
According to the Ghanaian president, the draft agreement included provisions for transmitting Ghana’s pathogen profiles and medical data to the United States. He also stated that the text obligated Ghana to provide counterpart funding and contained clauses concerning control over medical products entering the country.
For Mahama, these conditions were simply “humiliating.”
What Washington was actually asking for
The matter deserves scrutiny beyond the headline-grabbing phrase.
Ghana did not reject a $100 million package merely because it originated from the United States. The core issue lies in the conditions tied to the funding.
The proposed agreement, valued at around $300 million overall, would have provided Ghana with approximately $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, indicated that certain provisions would have allowed access to sensitive health data under circumstances that could potentially identify individuals. In his view, the scope of that access went well beyond what is typically necessary.
The BMJ also reported that the Ghanaian draft envisioned access to health data and pathogen information for 16 American companies. The journal noted, however, that several clauses in the new US health agreements remain difficult to examine publicly, as not all negotiated texts have been released.
A nuance is therefore warranted: it would be excessive to claim the United States was demanding unrestricted access to “all Ghanaians’ medical data.” What is documented, however, are Ghanaian concerns about the extent of access to health data and pathogen information.
Why this data matters so much
Behind medical records lies a genuine question of power.
Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed, and how outbreaks are evolving.
Pathogen data can also carry considerable scientific value. It can contribute to research on vaccines, treatments, and surveillance of emerging epidemics.
This is precisely what fuels concerns among several African governments.
In February 2026, Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already voiced serious concerns about provisions related to data and pathogen sharing in the new US health agreements. Some agreements required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.
Ghana is therefore not an isolated case.
Accra no longer wants to depend entirely on foreign aid
The rejection also comes in a particular context.
Since the suspension of a large portion of US aid programs, Ghana has sought to reduce its reliance on external funding. In February 2025, the Ghanaian presidency already estimated the shortfall caused by the suspension of USAID funding at $156 million, with $78.2 million directly affecting essential health programs.
The Mahama government is now pushing the idea of “health sovereignty.”
This direction was reinforced in September with the launch of the report A Sovereign Future for Health, presented as part of the Accra Reset initiative. The document proposes reducing Southern countries’ dependence on external funding and strengthening their own health systems.
Accra’s message is therefore relatively clear: Ghana wants to continue working with foreign partners, but on the basis of agreements it considers more balanced.
Another point of friction: medicines
The other element revealed by Mahama is particularly sensitive.
According to the president, the draft agreement stipulated that certain medicines and medical products supplied under the program would not be subject to controls by Ghana’s Food and Drugs Authority (FDA).
This claim has not been publicly confirmed in detail by the US government, which, when questioned, said it does not comment on the details of bilateral negotiations.
But if this provision indeed matched the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health funding should not lead to reducing the national regulator’s ability to control medical products used on its territory.
And the American response?
Washington has not publicly detailed the contested clauses.
A US State Department spokesperson said the United States does not disclose details of bilateral negotiations, while stating that Washington is still seeking ways to strengthen its partnership with Ghana.
This absence of full publication of the text therefore prevents definitive answers to certain essential questions.
Exactly what data would have been accessible?
To which American companies or institutions?
Under what circumstances could individuals have been identified?
How long would the data have been retained?
What legal guarantees would have protected Ghanaian patients?
On these points, public information remains incomplete.
Ghana opens a debate that goes beyond Ghana
The real issue in this affair may lie there.
For decades, many African health systems have depended on funding, medicines, equipment, and programs from abroad. These partnerships have saved lives and fought major diseases.
But the digital transformation of health is now changing the nature of cooperation.
Aid is no longer just about money, medicines, or equipment. It can also provide access to a strategic resource: data.
And Ghana has just reminded the world that it intends to retain control of that resource.
John Mahama says his government rejected the draft after review by the Ministry of Health and its passage before the Cabinet. He also says the decision had the support of the entire government and that the rejection was decided very quickly.
Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programs.
But for Accra, the choice seems deliberate:
better to seek other partners than to conclude an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.
The question Ghana now poses to its foreign partners is simple:
When Africa receives aid to treat its populations, must it also surrender control of information about those populations?
The debate is probably only just beginning.
